
Achieve Life Sciences, Inc.: shareholders and insiders
Price
$5.56
November 20, 2026Market cap $612M
What Ploutos Investor adds for Achieve Life Sciences
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Reading the newest filings from the SEC. This part fills in on its own in a few seconds.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- TPG Gp Awith 2 more personsShare of class12.6%
- Logos Global Management LPwith 7 more personsShare of class9.99%
- venBio Global Strategic Fund V, L.P.with 1 more personShare of class9.99%
- Paradigm BioCapital Advisors LPwith 3 more personsShare of class9.20%
- Franklin Resources, Inc.with 3 more personsShare of class8.30%
- Frazier Life Sciences Public Fund, L.P.with 5 more personsShare of class6.50%
- Alyeska Investment Group, L.P.with 2 more personsShare of class5.60%
- JANUS HENDERSON GROUP Ltd.Share of class5.40%
- Venrock Healthcare Capital Partners III, L.P.with 6 more personsShare of class5.20%
- BlackRock, Inc.Share of class5.10%
- Vivo Opportunity Fund Holdings, L.P.with 5 more personsShare of class5.00%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| TPG Gp Awith 2 more persons | 12.6% | 13.76M | Apr 24, 2026 | 13D | |
| Logos Global Management LPwith 7 more persons | 9.99% | 10.54M | Aug 17, 2026 | 13G | |
| venBio Global Strategic Fund V, L.P.with 1 more person | 9.99% | 10.74M | Apr 27, 2026 | 13D | |
| Paradigm BioCapital Advisors LPwith 3 more persons | 9.20% | 9.90M | Apr 24, 2026 | 13G | |
| Franklin Resources, Inc.with 3 more persons | 8.30% | 8.88M | Jul 28, 20266 filings since Oct 31, 2024 | 13G/A | |
| Frazier Life Sciences Public Fund, L.P.with 5 more persons | 6.50% | 6.63M | Apr 24, 2026 | 13G | |
| Alyeska Investment Group, L.P.with 2 more persons | 5.60% | 2.98M | Nov 14, 20252 filings since Aug 14, 2025 | 13G/A | |
| JANUS HENDERSON GROUP Ltd. | 5.40% | 5.50M | Aug 13, 2026 | 13G | |
| Venrock Healthcare Capital Partners III, L.P.with 6 more persons | 5.20% | 5.50M | Apr 24, 2026 | 13G | |
| BlackRock, Inc. | 5.10% | 5.27M | Jul 27, 20262 filings since Jul 16, 2025 | 13G | |
| Vivo Opportunity Fund Holdings, L.P.with 5 more persons | 5.00% | 5.31M | Jul 8, 2026 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
TPG Gp A12.6%From the filing of Apr 24, 2026
The information set forth in or incorporated by reference in Items 2, 3, 5 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. Securities Purchase Agreement TPG Auriga entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with the Issuer, dated as of April 15, 2026, pursuant to which it agreed to purchase, and the Issuer agreed to sell and issue, 6,877,580 shares of Common Stock and 6,877,580 accompanying Warrants at a collective price of $3.635 per combination of share of Common Stock and accompany Warrant (the "Private Placement"). On April 17, 2026, the Private Placement closed (the "Closing"). The aggregate purchase…
From the filing of Apr 24, 2026venBio Global Strategic Fund V, L.P.10.0%From the filing of Apr 27, 2026
The response to Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Persons acquired the securities reported herein for investment purposes. Subject to a number of factors, including market conditions and their general investment and trading policies, the Reporting Persons may, in the ordinary course of their business, dispose of the shares of Common Stock that they beneficially own. These dispositions may occur in open market transactions, privately negotiated transactions, or through other methods. Additionally, Fund V may distribute the shares of Common Stock that it directly holds to its limited partners. Dr. Royston, who is a member of General Partner…
From the filing of Apr 27, 2026
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
No well-known manager
None of the managers we track held Achieve Life Sciences shares in their latest 13F.
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.11%
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.08%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.06%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.03%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.02%
- IWMiShares Russell 2000 ETFWeight in the fund0.02%
- VXFVanguard Extended Market Index FundWeight in the fund0.01%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
8 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Achieve Life Sciences's filings show?
Who buys and sells is one part of Achieve Life Sciences's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.